Dynaflow technology finds favour with big pharma

Swedish biotech tools company Cellectricon has received orders from three of the top five pharmaceutical companies for its Dynaflow technology.

Cellectricon's Dynaflow microfluidic chip is a ground-breaking drug screening tool that can be used by pharmaceutical companies to perform drug discovery with high speed and accuracy.

It is based on a revolutionary microfluidic concept offering higher-throughput screening for drugs targeting ion channels, which are instrumental for brain and heart disease therapy. The Dynaflow technology, which is due for large-scale launch in August, is said to offer dramatic productivity increase: several hundred compounds acting on ligand- and voltage-gated ion channels can be screened in one working day, compared with the current average of 10 screenings per day.

'We are extremely pleased that three of the top five pharmaceutical companies have shown such a strong interest in our technology and their orders are proof that Dynaflow drug-screening technology will be adopted by others,' said Jakob Lindberg, ceo of Cellectricon. Earlier this spring Cellectricon received a breakthrough order from AstraZeneca for the patented Dynaflow technology.

Formed in 2000, Cellectricon is a biotechnology tools company that develops microfabricated cell-based tools for the pharmaceutical and biotechnology industries. It works at the interface between microtechnology and biology, inventing products that will allow productivity increases primarily in the drug discovery process. The company's patent portfolio includes high-throughput electrophysiology, patch-clamp, microfluidics, microfabrication, and electroporation.